<DOC>
	<DOCNO>NCT01245764</DOCNO>
	<brief_summary>The study design determine safety , tolerability immunogenicity 3-dose regimen GARDASIL™ administer healthy female 9 26 year age , Sub-Saharan Africa . Data current study need order complement exist extensive safety data GARDASIL™ clinical trial program , confirm GARDASIL™ may administer safely induce immune response population live Sub-Saharan Africa , GARDASIL™ previously study region world .</brief_summary>
	<brief_title>GARDASIL™ Study Healthy Females Between 9 26 Years Age Sub-Saharan Africa ( V501-046 )</brief_title>
	<detailed_description>In Phase A study , healthy female 9 12 year age randomize ( 4:1 ) receive 3-dose regimen GARDASIL™ placebo , 13 26 year old receive GARDASIL™ . In Phase B study , participant receive placebo Phase A option receive 3-dose regimen GARDASIL™ .</detailed_description>
	<mesh_term>Papillomavirus Infections</mesh_term>
	<criteria>Inclusion Criteria : Healthy subject native living participate SubSaharan African country . Subject agree provide study personnel primary telephone number well alternate telephone number followup purpose . If potential subject telephone number , subject must provide address may contact . Postpubertal female subject must pregnant Subjects sexually active must agree use effective contraception remain abstinent Month 7 study . Subjects yet sexual intercourse must either agree remain abstinent Month 7 study , become sexually active vaccination phase study , use effective contraception Month 7 . Subjects sexual intercourse two week prior enrollment must use effective contraception define . ( Emergency contraception consider effective contraception enrollment study . ) Exclusion Criteria : Subject pregnant determine positive pregnancy test Subject temperature ≥ 37.8 °C ≥ 100 °F within 24 hour prior first injection . Subject currently enrol another clinical study investigational agent agent . Subject history know prior vaccination HPV vaccine , previously enrol HPV vaccine study receive either active agent placebo . Subject receive inactivated vaccine within 14 day prior enrollment live vaccine within 21 day prior enrollment . Subject history severe allergic reaction agent ( e.g. , swell mouth throat , difficulty breathing , hypotension , shock ) require medical intervention . Subject know allergy vaccine component , include aluminum , yeast BENZONASE™ ( nuclease , Nycomed™ [ use remove residual nucleic acid vaccine ] ) . Subject receive immune globulin preparation bloodderived product within 6 month prior first injection , plan receive product course study . Subject history splenectomy , know autoimmune disorder ( e.g. , systemic lupus erythematosus , rheumatoid arthritis ) , receive immunosuppressive ( e.g. , substances treatment know diminish immune response radiation therapy , administration antimetabolite , antilymphocytic serum , systemic corticosteroid ) . Individuals receive periodic treatment immunosuppressive , define least 3 course systemic corticosteroid last least 1 week duration year prior enrollment , exclude . Subjects use topical steroid ( i.e. , inhale nasal ) eligible vaccination . Subject immunocompromised diagnosed Human Immunodeficiency Virus ( HIV ) infection Subject know thrombocytopenia coagulation disorder would contraindicate intramuscular injection . Subject know sickle cell anemia disease , active malaria active tuberculosis . Subject condition opinion investigator might interfere evaluation study objective . Subject history recent ongoing alcohol drug abuse . Female subject prior history abnormal Pap test show squamous intraepithelial lesion ( SIL ) , atypical squamous cell undetermined significance ( ASCUS ) , atypical squamous cell , rule high grade lesion ( ASCH ) , biopsy show cervical intraepithelial neoplasia ( CIN ) bad . Subject prior history ( Day 1 ) genital wart treatment genital wart . Subject &gt; 4 lifetime sexual partner . Subject undergone hysterectomy removal cervix . Subject plan permanently relocate area prior completion study leave extend period time study visit would need schedule .</criteria>
	<gender>Female</gender>
	<minimum_age>9 Years</minimum_age>
	<maximum_age>26 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Cervical cancer</keyword>
	<keyword>vulvar cancer</keyword>
	<keyword>vaginal cancer</keyword>
	<keyword>genital wart</keyword>
	<keyword>human papillomavirus</keyword>
</DOC>